Study of treatments for early onset Alzheimer's caused by genetic mutations
Part of Brain & nervous system, Mental health clinical trials.
This trial tests potential treatments for people who are at risk for or have early onset Alzheimer's disease due to a specific genetic mutation. It aims to find treatments that could slow or prevent symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You carry a mutation in the APP, PSEN1, or PSEN2 gene linked to early onset Alzheimer's, or you don't know your status but have a family history of one of these mutations.
- Your cognitive abilities are normal (no measurable memory or thinking problems yet).
- You have a study partner who can provide information about you during the study.
- You are willing to use highly effective contraception if you could become pregnant, and avoid pregnancy or breastfeeding during the trial.
- You do not have other serious medical conditions that could affect your cognition or participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a potential disease-modifying treatment for people who have a specific gene mutation that causes early-onset Alzheimer's disease. The goal is to see if the treatment can delay or prevent symptoms.
This study is a follow-up for people who completed a previous trial of an experimental treatment for early Alzheimer's disease. It will continue to test the treatment's safety and effects over a longer period.
This trial tests two medications (donanemab and RG6289) alone or together in people who carry a specific genetic mutation (PSEN1 E280A) that causes early-onset Alzheimer's disease. It aims to see if these drugs can slow or prevent memory loss.
This study follows people who are at risk for a specific inherited form of Alzheimer’s disease (because a parent has it). It helps researchers learn how the disease starts and changes over time, especially in people who still feel cognitively normal.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
This study tests an experimental drug called RO7568282 for people in the early stages of Alzheimer's disease. The goal is to see if it is safe and whether it can slow down memory loss and thinking problems.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.